BAFF is the main regulated element of the BAFF/APRIL system, and its serum concentrations were elevated in the majority of our IFN-β-treated MS patients and were associated with more severe clinical disease, whereas the opposite trend was observed for BAFFR. The gene discussed is TNFSF13B; the disease is myeloid sarcoma.